| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Suhaib Hattab, Layth Qasarweh, Malek Ahmaro, Yazid Atatre, Yasin Tayem, Mazen Ali, Haitham Jahram. Prescribing patterns of psychotropic medications in psychiatric disorders: a descriptive study from Palestine. International journal of clinical pharmacy. vol 43. issue 4. 2021-10-15. PMID:33411103. |
the most commonly prescribed drugs were typical antipsychotics for schizophrenia, bipolar and schizoaffective disorders, selective serotonin reuptake inhibitors for depression and tricyclic anti-depressants for anxiety. |
2021-10-15 |
2023-08-13 |
Not clear |
| Shami Kanekar, Chandni Sheth, Hendrick Ombach, Jadeda Brown, Michael Hoffman, Robert Ettaro, Perry Rensha. Sex-based changes in rat brain serotonin and behavior in a model of altitude-related vulnerability to treatment-resistant depression. Psychopharmacology. vol 238. issue 10. 2021-10-15. PMID:34159421. |
sex-based changes in rat brain serotonin and behavior in a model of altitude-related vulnerability to treatment-resistant depression. |
2021-10-15 |
2023-08-13 |
rat |
| Shami Kanekar, Chandni Sheth, Hendrick Ombach, Jadeda Brown, Michael Hoffman, Robert Ettaro, Perry Rensha. Sex-based changes in rat brain serotonin and behavior in a model of altitude-related vulnerability to treatment-resistant depression. Psychopharmacology. vol 238. issue 10. 2021-10-15. PMID:34159421. |
depression and ssri resistance are linked to disrupted serotonergic function, and hypobaric hypoxia may reduce the oxygen-dependent synthesis of serotonin. |
2021-10-15 |
2023-08-13 |
rat |
| Daniela Schul. Depression development: From lifestyle changes to motivational deficits. Behavioural brain research. vol 395. 2021-10-13. PMID:32758506. |
as a result, a dynamic model of depression development is proposed, which views depression as a cumulative process, where different symptoms develop at different stages, referred to as early, intermediate, and advanced, that require treatment with different pharmaceutical agents, that is, selective serotonin reuptake inhibitors early on and dopamine-based antidepressants at the advanced stage. |
2021-10-13 |
2023-08-13 |
Not clear |
| Genisson R Santos, Laise P A Chiari, Aldineia P da Silva, Célio F Lipinski, Aline A Oliveira, Kathia M Honorio, Alexsandro Gama de Sousa, Albérico B F da Silv. A partial least squares and artificial neural network study for a series of arylpiperazines as antidepressant agents. Journal of molecular modeling. vol 27. issue 10. 2021-10-12. PMID:34558019. |
5-ht receptor, known as serotonin, is considered the key in depression treatment. |
2021-10-12 |
2023-08-13 |
Not clear |
| Janne Kaergaard Mortensen, Grethe Anderse. Safety considerations for prescribing SSRI antidepressants to patients at increased cardiovascular risk. Expert opinion on drug safety. 2021-10-12. PMID:34569395. |
with the development of selective serotonin reuptake inhibitors (ssri), a relatively uncomplicated treatment of depression and a safer alternative to tricyclic antidepressants was introduced. |
2021-10-12 |
2023-08-13 |
Not clear |
| Guy M Goodwi. Revisiting Treatment Options for Depressed Patients with Generalised Anxiety Disorder. Advances in therapy. vol 38. issue Suppl 2. 2021-10-11. PMID:34417993. |
the initial treatment of a patient with depression and symptoms of anxiety should be with an agent that is approved for both major depressive disorder and gad, such as a selective serotonin reuptake inhibitor. |
2021-10-11 |
2023-08-13 |
Not clear |
| Gwenn S Smith, Clifford I Workman, Hillary Protas, Yi Su, Alena Savonenko, Hiroto Kuwabara, Neda F Gould, Michael Kraut, Jin Hui Joo, Ayon Nandi, Dimitri Avramopoulos, Eric M Reiman, Kewei Che. Positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares. Translational psychiatry. vol 11. issue 1. 2021-10-11. PMID:34518514. |
positron emission tomography imaging of serotonin degeneration and beta-amyloid deposition in late-life depression evaluated with multi-modal partial least squares. |
2021-10-11 |
2023-08-13 |
mouse |
| Carolina Costa, Miguel Semedo, Sandrine P Machado, Virginia Cunha, Marta Ferreira, Ralph Urbatzk. Transcriptional analyses reveal different mechanism of toxicity for a chronic exposure to fluoxetine and venlafaxine on the brain of the marine fish Dicentrarchrus labrax. Comparative biochemistry and physiology. Toxicology & pharmacology : CBP. vol 250. 2021-10-08. PMID:34454087. |
selective serotonin reuptake inhibitor (ssri) and serotonin norepinephrine reuptake inhibitor (snri) are prescribed for clinical depression and detected in aquatic ecosystems. |
2021-10-08 |
2023-08-13 |
Not clear |
| Yéssica P López-Echeverri, Kelly J Cardona-Londoño, Jhonny F Garcia-Aguirre, Mary Orrego-Cardoz. Effects of Serotonin Transporter and Receptor Polymorphisms on Depression. Revista Colombiana de psiquiatria (English ed.). 2021-10-07. PMID:34493397. |
effects of serotonin transporter and receptor polymorphisms on depression. |
2021-10-07 |
2023-08-13 |
Not clear |
| Yéssica P López-Echeverri, Kelly J Cardona-Londoño, Jhonny F Garcia-Aguirre, Mary Orrego-Cardoz. Effects of Serotonin Transporter and Receptor Polymorphisms on Depression. Revista Colombiana de psiquiatria (English ed.). 2021-10-07. PMID:34493397. |
serotonin is highly implicated in the regulation of emotional state and the execution of cognitive tasks, so much so that the serotonin transporter genes (5-htt, slc6a4) and the serotonin receptor genes (htr1a, htr1b, htr2a) have become the perfect candidates when studying the effects that these genes and their polymorphic variations have on depression characteristics. |
2021-10-07 |
2023-08-13 |
Not clear |
| M A Schiele, P Zwanzger, K Schwarte, V Arolt, B T Baune, K Domschk. Serotonin Transporter Gene Promoter Hypomethylation as a Predictor of Antidepressant Treatment Response in Major Depression: A Replication Study. The international journal of neuropsychopharmacology. vol 24. issue 3. 2021-10-06. PMID:33125470. |
serotonin transporter gene promoter hypomethylation as a predictor of antidepressant treatment response in major depression: a replication study. |
2021-10-06 |
2023-08-13 |
Not clear |
| Amber N Edinoff, Juliana M Fort, Joshua J Woo, Christopher D Causey, Caroline R Burroughs, Elyse M Cornett, Adam M Kaye, Alan D Kay. Selective Serotonin Reuptake Inhibitors and Clozapine: Clinically Relevant Interactions and Considerations. Neurology international. vol 13. issue 3. 2021-10-02. PMID:34564289. |
the monoamine hypothesis of depression attributes the symptoms of major depressive disorders to imbalances of serotonin, noradrenaline, and dopamine in the limbic areas of the brain. |
2021-10-02 |
2023-08-13 |
Not clear |
| L Perez-Caballero, M L Soto-Montenegro, M Desco, J A Mico, E Berrocos. Sustained escitalopram administration affects glucose metabolism in the rat brain. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 51. 2021-10-01. PMID:34022746. |
escitalopram is a selective serotonin reuptake inhibitor (ssris) antidepressant, drug that is currently used as first-line agents for the treatment of depression and it is also used in the treatment of other psychiatric disorders. |
2021-10-01 |
2023-08-13 |
rat |
| Robyn P Thom, Michelle L Palumbo, Claire Thompson, Christopher J McDougle, Caitlin T Ravichandra. Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study. Brain sciences. vol 11. issue 9. 2021-10-01. PMID:34573236. |
selective serotonin reuptake inhibitors for the treatment of depression in adults with down syndrome: a preliminary retrospective chart review study. |
2021-10-01 |
2023-08-13 |
Not clear |
| Robyn P Thom, Michelle L Palumbo, Claire Thompson, Christopher J McDougle, Caitlin T Ravichandra. Selective Serotonin Reuptake Inhibitors for the Treatment of Depression in Adults with Down Syndrome: A Preliminary Retrospective Chart Review Study. Brain sciences. vol 11. issue 9. 2021-10-01. PMID:34573236. |
the current literature on the treatment of depression in adults with ds is limited to case series published more than two decades ago, prior to the widespread use of modern antidepressant medications such as selective serotonin reuptake inhibitors (ssris). |
2021-10-01 |
2023-08-13 |
Not clear |
| A N Savostyanov, D V Bazovkina, S А Lashin, S S Tamozhnikov, A E Saprygin, T N Astakhova, U N Kavai-Ool, N V Borisova, A G Karpov. Comprehensive analysis of the 5-HTTLPR allelic polymorphism effect on behavioral and neurophysiological indicators of executive control in people from different ethnic groups in Siberia. Vavilovskii zhurnal genetiki i selektsii. vol 25. issue 5. 2021-10-01. PMID:34595380. |
the allelic polymorphism of the serotonin transporter's gene 5-httlpr is considered as one of the factors determining an individual genetic predisposition to the development of a wide range of affective disorders, including depression. |
2021-10-01 |
2023-08-13 |
human |
| Elmars Rancans, Janos Zambori, Mads Dalsgaard, Corine Baayen, Johan Areberg, Anders Ettrup, Ioana Flore. Intravenous vortioxetine to accelerate onset of effect in major depressive disorder: a 7-day randomized, double-blind, placebo-controlled exploratory study. International clinical psychopharmacology. vol 35. issue 6. 2021-09-28. PMID:32784346. |
patients (ages 18-65 years) hospitalized per standard-of-care with major depressive disorder, who were currently treated with a selective serotonin reuptake inhibitor or serotonin-norepinephrine reuptake inhibitor for a major depressive episode [montgomery-Åsberg depression rating scale (madrs) total score ≥ 30], received one dose of single-blind iv placebo (1-day placebo lead-in period) before being randomly switched to either single-dose iv vortioxetine 25 mg plus daily oral vortioxetine 10 mg (n = 39), or iv placebo plus daily oral placebo (n = 41). |
2021-09-28 |
2023-08-13 |
Not clear |
| Grzegorz Ślifirski, Marek Król, Jadwiga Turł. 5-HT Receptors and the Development of New Antidepressants. International journal of molecular sciences. vol 22. issue 16. 2021-09-28. PMID:34445721. |
the complex nature of the serotonergic system and interactions with other neurochemical systems indicate that the development of depression may be mediated by various pathomechanisms, the common denominator of which is undoubtedly the disturbed transmission in central 5-ht synapses. |
2021-09-28 |
2023-08-13 |
human |
| Grzegorz Ślifirski, Marek Król, Jadwiga Turł. 5-HT Receptors and the Development of New Antidepressants. International journal of molecular sciences. vol 22. issue 16. 2021-09-28. PMID:34445721. |
the aim of this article is to summarize the search for new antidepressants in recent years, focusing primarily on the possibility of benefiting from interactions with various 5-ht receptors in the pharmacotherapy of depression. |
2021-09-28 |
2023-08-13 |
human |